Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, Okinawa, Japan.
J Obstet Gynaecol Res. 2021 Feb;47(2):833-837. doi: 10.1111/jog.14589. Epub 2020 Dec 9.
Nasal septal perforation caused by bevacizumab is rarely reported in other cancers such as ovarian cancer and breast cancer, but it has not been reported in cervical cancer. A 48-year-old woman with a medical history of chronic allergic rhinitis was diagnosed stage 4B (T2bN1M0) cervical cancer and paclitaxel and carboplatin along with bevacizumab (triweekly) were administered. After eight courses of chemotherapy, nasal septal perforation was noted. The possibility of nasal septal perforation by bevacizumab was considered by excluding other causes. We report the first case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.
贝伐珠单抗引起的鼻中隔穿孔在卵巢癌和乳腺癌等其他癌症中很少见报道，但在宫颈癌中尚未见报道。一位 48 岁的女性，有慢性过敏性鼻炎病史，被诊断为 4B 期（T2bN1M0）宫颈癌，接受紫杉醇和卡铂联合贝伐珠单抗（每三周一次）治疗。化疗 8 个疗程后，发现鼻中隔穿孔。通过排除其他原因，考虑贝伐珠单抗引起鼻中隔穿孔的可能性。我们报告了首例贝伐珠单抗治疗晚期宫颈癌引起鼻中隔穿孔的病例。
